Stenting Iliac Obstruction and Embolization of the Periprostatic Venous Plexus for Pelvic Pain in Men

Wednesday, September 20, 2023

9:39 AM – 9:49 AM US EDT

Location: Grand Ballroom A

Introduction, Objectives, and/or Purpose:

Purpose: To evaluate retrospectively the safety and efficacy of staged stenting nonthrombotic iliac vein lesions (NIVL) and retrograde embolization of the periprostatic venous plexus for pelvic pain in men with pelvic congestion syndrome.

Methods: From October 2019 through August 2022, 27 men with pelvic pain and dysuria due to pelvic congestion syndrome were treated in our hospitals. The average age of patients was 31 ± 7 years. All patients had dilated veins of the periprostatic plexus. The first stage of treatment was NIVL (May-Turner syndrome) stenting with dedicated venous stents (total 33 stents). All stenting was performed under the IVUS control. After 6 months, in case of a poor clinical result, the second stage was performed by embolization of the expanded branches of the internal iliac veins and the venous periprostatic plexus (total 8 patients). Selective occlusion was achieved using a combination of 3% aethoxysclerol and endovascular coils accessed through the veins of the arm.

Results: Technical success was achieved in all 27 patients (100%). Six months after stenting, pain and dysuria reduction was achieved in 19 (70,1%) patients. Six months after second stage (embolization), pain and dysuria reduction was achieved in total in 24 (88,9%) patients. 3 (11,1%) patients did not notice any improvement. No complications were encountered.

Conclusion(s): Staged NIVL stenting and retrograde embolization of the periprostatic venous plexus for pelvic pain in men is a safe and effective procedure.

Presenting Author(s)

AP

Alexey Pankov, PhD

MD
Volynskaya Hospital
Moscow, Moskva, Russia

Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose.

PDF

Co-Author(s)

NZ

Narek Zakaryan, PhD

MD
Volynskaya Hospital
Moscow, Russia

Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose.
EM

Eugeniy Molokhoev, PhD

MD
Volynskaya Hospital
Moscow, Russia

Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose.
EB

Eugeniy Barinov, PhD

MD
Volynskaya Hospital
Moscow, Russia

Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose.
AK

Alexander Kapto, PhD

MD
SM-clinic (Moscow)
Moscow, Russia

Disclosure(s):
The forementioned Program Planner, Faculty, Author, Moderator, or Speaker, has declared for this educational activity, having no relevant financial relationship(s) with ineligible companies to disclose.